Literature DB >> 15005582

Nonpenetrating deep sclerectomy: a 6-year retrospective study.

Y Lachkar1, J Neverauskiene, M N Jeanteur-Lunel, H Gracies, M Berkani, M Ecoffet, J Kopel, G Kretz, P Lavat, M Lehrer, F Valtot, P Demailly.   

Abstract

PURPOSE: Nonpenetrating trabeculectomy, also called nonpenetrating deep sclerectomy (NPDS), is a filtering surgery where the internal wall of Schlemm's canal is excised, allowing subconjunctival filtration without actually entering the anterior chamber. This, technique was developed to minimize the complications of trabeculectomy. The authors investigated its safety and efficacy in a retrospective noncomparative study.
METHODS: A total of 258 eyes (179 patients, mean age 61.4 +/- 11.56 years) with uncontrolled open angle glaucoma with prior medical therapy were treated. NPDS with a biocompatible collagen device (157 eyes) sutured to deep scleral bed or with the use of a 5-fluorouracil sponge (90 eyes) were analyzed. The main outcome measure was postoperative intraocular pressure (IOP) with an average follow-up of 54.4 +/- 17.07 months (range 1-85). Efficacy was determined 1 month, 3 months, and every 6 months after the procedure for 6 years.
RESULTS: Mean preoperative IOP was 24.47 +/- 5.92 mmHg. Mean postoperative IOP was 14.44 +/- 5.31 mmHg (average lowering of the IOP was 38.94 +/- 23.81%) at 1 month, 15.16 +/- 4.57 mmHg (35.73 +/- 21.35%) at 3 months, 15.87 +/- 4.24 mmHg (32.45 +/- 20.52%) at 6 months, 16.32 +/- 4.53 mmHg (29.96 +/- 23.69%) at 12 months, 17.12 +/- 4.45 mmHg (26.51 +/- 23.93%) at 18 months, 16.77 +/- 4.44 mmHg (28.18 +/- 21.73%) at 24 months, 16.43 +/- 4.15 mmHg (28.89 +/- 23.69%) at 30 months, 16.34 +/- 4.12 mmHg (30.05 +/- 21.61%) at 36 months, 16.16 +/- 4.01 mmHg (30.06 +/- 22.55%) at 42 months, 15.71 +/- 3.74 mmHg (32.49 +/- 19.08%) at 48 months, 15.61 +/- 3.48 mmHg (31.26 +/- 21.01%) after 5 years, and 15.81 +/- 3.79 mmHg (33.73 +/- 20.9%) after 6 years. YAG goniopuncture was performed in 47.3% of cases with a mean follow-up of 12 +/- 13 months. These goniopunctures were effective in lowering IOP after a long-term follow-up (24 months). Additional 5-fluorouracil injections were used in 7% of cases. Visual field (Octopus or Humphrey mean defect and corrected loss variance or loss variance) was not modified (p < 0.01). Number of preoperative glaucoma medications was 2.01 +/- 0.58 and number of postoperative glaucoma medications was 0.85 +/- 0.92. Complications were peroperative microperforations in 27 eyes (10.5%), shallow anterior chamber in 2 eyes, hyphema in 2 eyes (0.8%), cataract in 5 eyes (2%), and dellen in 1 eye (0.4%). No cases of endophthalmitis or choroidal detachment were found. After surgery, 23 eyes (8.9%) required a new filtering surgical procedure, and diode laser cyclophotocoagulation was necessary in 2 eyes (0.8%). The probability success rate, defined as an IOP lower than 21 mmHg, was 66.46% (Kaplan Meier) at 60 months off all glaucoma medications and 80.32% with medical or new surgical treatment.
CONCLUSIONS: NPDS appears to be an effective and safe filtering procedure for lowering IOP and could be an alternative to trabeculectomy in open angle glaucoma with the advantage of having fewer complications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15005582     DOI: 10.1177/112067210401400105

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  23 in total

1.  Building a safer trabeculectomy.

Authors:  S Lin
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

2.  Nd:YAG laser goniopuncture in viscocanalostomy: penetration in non-penetrating glaucoma surgery.

Authors:  Mehmet Numan Alp; Alper Yarangumeli; Ozlem Gurbuz Koz; Gulcan Kural
Journal:  Int Ophthalmol       Date:  2009-05-29       Impact factor: 2.031

3.  IOP-lowering effects for the application of human umbilical vein in non-penetrating deep sclerostomy in rabbits.

Authors:  Yang Yang; Yu Di; Dong-Mei Gui; Zhi-Li Liu; Xin Liu; Dian-Wen Gao
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

4.  Trabeculectomy combined with deep sclerectomy and scleral flap suture tension adjustment under an anterior chamber maintainer: a new modification of trabeculectomy.

Authors:  Ozcan R Kayikcioglu; Sinan Emre; Ziya Kaya
Journal:  Int Ophthalmol       Date:  2009-12-04       Impact factor: 2.031

5.  Deep sclerectomy with supraciliary hema implant (Esnoper® V-2000): results and complications.

Authors:  Jordi Loscos; Xavier Valldeperas; Klaus Langohr; Klaus Langhor; Àngels Parera; Pau Romera; Antoni Sabala; Julio de la Cámara
Journal:  Int Ophthalmol       Date:  2015-01-30       Impact factor: 2.031

6.  Exit strategies in canaloplasty: intraoperative conversion into 180-degree trabeculotomy or 360-degree trabeculotomy in cases of unsuccessful catheterisation of Schlemm's canal: influence of degree of canal cleavage.

Authors:  Omar Alnahrawy; Gunnar Blumenstock; Focke Ziemssen; Peter Szurman; Martin Alexander Leitritz; Spyridon Dimopoulos; Bogomil Voykov
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-18       Impact factor: 3.117

7.  Risk assessment of sudden visual loss following non-penetrating deep sclerectomy in severe and end-stage glaucoma.

Authors:  Igor Leleu; Benjamin Penaud; Esther Blumen-Ohana; Thibault Rodallec; Raphaël Adam; Olivier Laplace; Jad Akesbi; Jean-Philippe Nordmann
Journal:  Eye (Lond)       Date:  2019-01-24       Impact factor: 3.775

8.  Efficacy and safety of deep sclerectomy in uveitic glaucoma.

Authors:  Saleh A Al Obeidan; Essam A Osman; Abdulrahman M Al-Muammar; Ahmed M Abu El-Asrar
Journal:  Int Ophthalmol       Date:  2008-06-19       Impact factor: 2.031

9.  Deep sclerectomy and low dose mitomycin C: a randomised prospective trial in west Africa.

Authors:  C Mielke; V K Dawda; N Anand
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

10.  SKGEL® implant versus T-Flux® implant in the contralateral eye in deep sclerectomy with phacoemulsification: long-term follow-up.

Authors:  Frank Schreyger; Gabor Scharioth; Holger Baatz
Journal:  Open Ophthalmol J       Date:  2008-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.